COMPPARE Newsletter: Summer 2021

A Message from Dr. Nancy Mendenhall

COMPPARE has achieved both a remarkable overall accrual rate and a remarkable accrual rate of minorities. In fact, the study stands to become a model for patient-centric clinical research in the future. Read Dr. Mendenhall’s message.

Partner Site Spotlight: The Hampton University Proton Therapy Institute

Recently celebrating ten years in operation, Hampton University Proton Therapy Institute has treated more than 3,100 patients to date and is the largest free-standing proton therapy cancer center in the world – follow the conversation here.

Genetic Tool Predicts Age-specific Risk for Developing Prostate Cancer

Researchers at the University of California San Diego School of Medicine have validated a more comprehensive genetic tool for predicting age of onset of aggressive prostate cancer – learn more about it.

COMPPARE Invited To Participate in Annual PCORI Meeting

The 7th annual meeting of the Patient-Centered Outcomes Research Institute will take place virtually in November. Dr. Nancy Mendenhall and Mr. Charles Griggs will contribute as panelists in a session entitled “The benefits of engagement: building partnerships to help move health research toward trust and equity” – read more.

Consortium Spotlight: Hampton Roads

Hampton, Virginia is one of the nation’s most diverse areas of the country, and with diversity comes more opportunity to understand and address health disparities. Learn about the Hampton Roads Prostate Health Forum and its focus on addressing these disparities.

COMPPARE Study Progress

Want the latest information on COMPPARE? Find out how many patients have enrolled and how many sites are currently enrolling patients on the COMPPARE Study Progress page.

Research reported in this newsletter was partially funded through a Patient-Centered Outcomes Research Institute (PCORI) Award (PCS-2017C1-0422). The views, statements, and opinions presented in this newsletter are solely the responsibility of the authors and do not necessarily represent the views of PCORI, its Board of Governors, or Methodology Committee.